Natera, Inc.

The company is a diagnostics provider specializing in cell-free DNA molecular assays and bioinformatics algorithms across oncology, women's health, and organ health. In oncology, it offers tests for molecular residual disease detection, recurrence monitoring, and therapy selection, serving oncology clinics, cancer researchers, and biopharmaceutical partners. In women's health, its portfolio includes non-invasive prenatal screening, carrier screening, and pregnancy loss evaluation. In organ health, it supplies tests to detect transplant rejection in heart, lung, and kidney recipients, as well as genetic panels for chronic kidney disease. It also licenses its cloud bioinformatics platform to external clinical laboratories.

The company is headquartered in Austin, Texas, with additional laboratory facilities in San Carlos, California, and Boulder, Colorado. Its commercial presence spans more than 80 countries globally through direct sales engagement and a network of over 100 laboratory and distribution partners.

Summary of the business section of Natera's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, our global workforce comprised 6,140 employees, of whom 6,135 were full time employees.”